A high oxfendazole dose to control porcine cysticercosis: Pharmacokinetics and tissue residue profiles

L. Moreno, Maria Teresa Lopez Urbina, C. Farias, G. Domingue, M. Donadeu, B. Dungu, H. H. García, Luis Antonio Gomez Puerta, C. Lanusse, Armando Emiliano Gonzalez Zariquiey

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Oxfendazole (OFZ) is efficacious for porcine cysticercosis at 30mg/kg. OFZ is not registered to be used at this dose. The assessment of the OFZ and metabolites [(fenbendazole sulphone (FBZSO2), fenbendazole (FBZ)] plasma pharmacokinetic and tissue residue profiles after its oral administration to pigs and the withdrawal period for human consumption were reported. Forty-eight pigs allocated into two groups received OFZ (30mg/kg) orally as a commercial (CF) or as experimental formulation (SMF). Samples (blood, muscle, liver, kidney and fat) were collected over 30days post-treatment and analyzed by HPLC. OFZ was the main compound recovered in plasma, followed by FBZSO2 and low FBZ concentrations. OFZ AUC0-LOQ (209.9±33.9μg·h/ml) and Cmax (5.40±0.65μg/ml) parameters for the CF tended to be higher than those for the SMF (AUC0-LOQ: 159.4±18.3μgh/ml, Cmax: 3.80±0.35μg/ml). The highest total residue (OFZ+FBZSO2+FBZ) concentrations were quantified in liver, followed by kidney, muscle and fat tissue. FBZSO2 residue levels were the highest found in muscle (0.68±0.39μg/g) and fat (0.69±0.39μg/g). In liver and kidney the highest residues corresponded to FBZ (5.29±4.36μg/g) and OFZ (2.86±0.75μg/g), respectively. A withdrawal time of 17days post-treatment was established before tissues are delivered for human consumption.

Original languageEnglish
Pages (from-to)3819-3825
Number of pages7
JournalFood and Chemical Toxicology
Issue number10
StatePublished - Oct 2012
Externally publishedYes

Bibliographical note

Funding Information:
Funding: This work was funded by the Bill and Melinda Gates Foundation through grants number 1016506 and 23981 and also funds from the Department for International Development (DFID) UK. HG is a Wellcome Trust Senior Research Fellow in Public Health. The funders had no role in study design; data collection, analysis, or interpretation; in writing the report, or in the decision to submit the article for publication.


  • Cysticercosis
  • Oxfendazole
  • Pharmacokinetics
  • Tissue residues
  • Withdrawal time

Fingerprint Dive into the research topics of 'A high oxfendazole dose to control porcine cysticercosis: Pharmacokinetics and tissue residue profiles'. Together they form a unique fingerprint.

Cite this